Sugi Predict

Sugi Predict / Compounds / SCHEMBL16639727

SCHEMBL16639727

SCHEMBL16639727

O=C(O)c1ccc2nc(CBr)c(CBr)nc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.70
▸ MEN1 O00255 5/20 0.70
▸ KMT2A Q03164 5/20 0.70
▸ NPC1 O15118 5/20 0.70
▸ TDP1 Q9NUW8 3/20 0.61
▸ KDM4E B2RXH2 5/20 0.56
▸ GAA P10253 4/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ HPGD P15428 4/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ MAPT P10636 4/20 0.51
▸ CDH1 P12830 1/20 0.51
▸ APC P25054 1/20 0.51
▸ CTNNB1 P35222 1/20 0.51
▸ TCF7L2 Q9NQB0 1/20 0.51
▸ HTT P42858 2/20 0.49
▸ RXFP1 Q9HBX9 2/20 0.49
▸ THRB P10828 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ POLB P06746 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26264034 0.84 NPC1 (0.50) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL16646581 0.84 KMT2A (0.50) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL24920215 0.84 NPC1 (0.54) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL30645370 0.84 KMT2A (0.50) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL17987760 0.83 NPC1 (0.49) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL30645374 0.83 NPC1 (0.49) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL5696651 0.82 TDP1 (0.77) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL21723107 0.82 TDP1 (0.77) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL24307522 0.81 NPC1 (0.55) RAB9AMEN1KMT2ANPC1TDP1
SCHEMBL24080415 0.80 NPC1 (0.50) RAB9AMEN1KMT2ANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025031383-A1 BIFUNCTIONAL LINKER COMPOUND, ANTIBODY DRUG CONJUGATE, PREPARATION METHOD FOR ANTIBODY DRUG CONJUGATE, AND USE OF ANTIBODY DRUG CONJUGATE 杭州爱科瑞思生物医药有限公司 2025-02-13 — — WO disclosed
CN-117157107-A Multifunctional antibody 西纳福克斯股份有限公司 2023-12-01 — — CN disclosed
CN-117069793-A Bifunctional linker compound, antibody drug conjugate, and preparation methods and applications thereof 杭州爱科瑞思生物医药有限公司 2023-11-17 — — CN disclosed
US-20230114866-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2023-04-13 — — US disclosed
CN-115768483-A Conjugates of antibodies and immune cell adaptors 西纳福克斯股份有限公司 2023-03-07 — — CN disclosed
CN-115666656-A Bilateral functionalization of antibodies by cycloaddition 西纳福克斯股份有限公司 2023-01-31 — — CN disclosed
EP-4090379-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES Synaffix B.V. (NL) 2022-11-23 — — EP disclosed
EP-4090376-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES Synaffix B.V. (NL) 2022-11-23 — — EP disclosed
WO-2021144313-A9 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2022-11-03 — — WO disclosed
CN-115243727-A Bilaterally functionalized antibodies via cycloaddition 西纳福克斯股份有限公司 2022-10-25 — — CN disclosed
WO-2021144314-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2021-07-22 — — WO disclosed
WO-2021144315-A1 CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS SYNAFFIX B.V. (NL) 2021-07-22 — — WO disclosed
WO-2017210288-A1 ANTIBODY DRUG CONJUGATES HAVING DERIVATIVES OF AMATOXIN AS THE DRUG SORRENTO THERAPEUTICS, INC. (US) 2017-12-07 — — WO disclosed
US-20170281758-A1 CALICHEAMICIN ANTIBODY DRUG CONJUGATES LINKING AN AMIDOACETYL GROUP TO A SUGAR MOIETY ON CALICHEAMICIN SORRENTO THERAPEUTICS, INC. 2017-10-05 — — US disclosed
US-20170224835-A1 Antibody Drug Conjugates SORRENTO THERAPEUTICS, INC. (US) 2017-08-10 — — US disclosed
US-20170224835-A1 Antibody Drug Conjugates SORRENTO THERAPEUTICS, INC. (US) 2017-08-10 — — US disclosed
WO-2016127081-A1 ANTIBODY DRUG CONJUGATES SORRENTO THERAPEUTICS, INC. (US) 2016-08-11 — — WO disclosed
WO-2015057876-A1 DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS SORRENTO THERAPEUTICS INC. (US) 2015-04-23 — — WO disclosed
US-20150105540-A1 DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS SORRENTO THERAPEUTICS INC. (US) 2015-04-16 — — US disclosed
US-20150105540-A1 DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS SORRENTO THERAPEUTICS INC. (US) 2015-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114866-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES FUT5, FUCA1, FUT6 RAB9A 3601/4885MEN1 568/4885KMT2A 2418/4885
US-20170281758-A1 CALICHEAMICIN ANTIBODY DRUG CONJUGATES LINKING AN AMIDOACETYL GROUP TO A SUGAR MOIETY ON CALICHEAMICIN CALU, STT3A, STT3B RAB9A 2052/4885MEN1 3974/4885KMT2A 3716/4885
US-20170224835-A1 Antibody Drug Conjugates DARS1, CD38, AADAC RAB9A 1025/4885MEN1 3485/4885KMT2A 244/4885
US-20150105540-A1 DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS ERBB2, ABCG2, DYNLL2 RAB9A 627/4885MEN1 3587/4885KMT2A 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.